Profile data is unavailable for this security.
About the company
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company is focused on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The Company’s Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608, Lirafugratinib (RLY-4008), and Migoprotafib (GDC-1971). RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor. RLY-4008, is a potent, selective, and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. GDC-1971 is an inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), as a monotherapy in patients with advanced or metastatic solid tumors.
- Revenue in USD (TTM)35.21m
- Net income in USD-322.83m
- Incorporated2015
- Employees304.00
- LocationRelay Therapeutics Inc399 Binney Street, 2Nd FloorCAMBRIDGE 02139United StatesUSA
- Phone+1 (617) 370-8837
- Fax+1 (302) 655-5049
- Websitehttps://relaytx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pharvaris NV | 0.00 | -126.85m | 1.09bn | 82.00 | -- | 2.96 | -- | -- | -2.66 | -2.66 | 0.00 | 6.85 | 0.00 | -- | -- | 0.00 | -42.13 | -36.09 | -45.04 | -38.27 | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | -32.15 | -- | -- | -- |
Travere Therapeutics Inc | 177.64m | -383.45m | 1.10bn | 380.00 | -- | 72.43 | -- | 6.18 | -4.99 | -1.88 | 2.31 | 0.1981 | 0.2759 | 0.7613 | 7.92 | 467,484.20 | -59.56 | -36.95 | -74.41 | -44.77 | 94.70 | 95.92 | -215.85 | -165.79 | 2.99 | -- | 0.9615 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
AnaptysBio Inc | 30.47m | -170.12m | 1.10bn | 117.00 | -- | 101.55 | -- | 36.22 | -6.34 | -6.34 | 1.14 | 0.3601 | 0.0645 | -- | 5.00 | 260,453.00 | -36.02 | -18.08 | -39.45 | -18.96 | -- | -- | -558.25 | -269.21 | -- | -- | 0.00 | -- | 66.78 | 27.97 | -27.11 | -- | -5.36 | -- |
CARGO Therapeutics Inc | 0.00 | -147.71m | 1.11bn | 116.00 | -- | 2.54 | -- | -- | -3.47 | -3.47 | 0.00 | 9.51 | 0.00 | -- | -- | 0.00 | -53.66 | -- | -59.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
Longboard Pharmaceuticals Inc | 0.00 | -64.74m | 1.14bn | 50.00 | -- | 3.87 | -- | -- | -2.16 | -2.16 | 0.00 | 7.58 | 0.00 | -- | -- | 0.00 | -34.15 | -- | -36.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
Phathom Pharmaceuticals Inc | 9.92m | -297.11m | 1.15bn | 452.00 | -- | -- | -- | 115.55 | -5.13 | -5.13 | 0.1717 | -3.99 | 0.0339 | 1.72 | -- | 21,942.48 | -101.68 | -83.26 | -115.19 | -93.77 | 80.15 | -- | -2,995.68 | -135,982.00 | 6.44 | -5.74 | 1.86 | -- | -- | -- | -1.96 | -- | -- | -- |
Cogent Biosciences Inc | 0.00 | -227.05m | 1.15bn | 164.00 | -- | 4.45 | -- | -- | -2.48 | -2.48 | 0.00 | 3.41 | 0.00 | -- | -- | 0.00 | -55.22 | -49.53 | -60.02 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
Prothena Corporation PLC | 217.25m | -50.92m | 1.16bn | 173.00 | -- | 1.98 | -- | 5.32 | -1.01 | -1.01 | 3.94 | 10.82 | 0.318 | -- | 829.18 | 1,255,757.00 | -7.45 | -14.20 | -8.16 | -15.11 | -- | -- | -23.44 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
Day One Biopharmaceuticals Inc | 8.19m | -167.48m | 1.21bn | 169.00 | -- | 3.94 | -- | 147.73 | -1.94 | -1.94 | 0.0948 | 3.50 | 0.0193 | -- | -- | 52,851.61 | -39.35 | -- | -45.70 | -- | 91.37 | -- | -2,044.43 | -- | 4.09 | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
Arcutis Biotherapeutics Inc | 132.06m | -198.76m | 1.22bn | 296.00 | -- | 6.50 | -- | 9.21 | -2.18 | -2.18 | 1.36 | 1.60 | 0.3451 | 0.8334 | 4.36 | 446,155.40 | -51.93 | -65.64 | -58.68 | -71.72 | 92.32 | -- | -150.51 | -1,513.03 | 8.19 | -5.94 | 0.5223 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
Tyra Biosciences Inc | 0.00 | -80.88m | 1.23bn | 49.00 | -- | 3.25 | -- | -- | -1.69 | -1.69 | 0.00 | 7.13 | 0.00 | -- | -- | 0.00 | -25.18 | -- | -25.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
Relay Therapeutics Inc | 35.21m | -322.83m | 1.23bn | 304.00 | -- | 1.48 | -- | 34.85 | -2.52 | -2.52 | 0.277 | 5.11 | 0.0406 | -- | -- | 109,003.10 | -37.22 | -28.55 | -39.91 | -29.54 | -- | -- | -916.92 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
Gyre Therapeutics Inc | 165.85m | -79.66m | 1.30bn | 593.00 | -- | 19.66 | -- | 7.81 | -0.8638 | -0.8638 | 1.43 | 0.7056 | 2.49 | -- | 17.81 | 279,674.50 | -103.20 | -73.59 | -167.87 | -99.94 | 96.15 | -- | -41.48 | -205.62 | 3.07 | -- | 0.00 | -- | 14,188.41 | 616.69 | -1,027.55 | -- | 86.95 | -- |
ARS Pharmaceuticals Inc | 500.00k | -44.84m | 1.36bn | 23.00 | -- | 6.33 | -- | 2,724.06 | -0.466 | -0.466 | 0.0052 | 2.22 | 0.0021 | -- | -- | 20,833.33 | -18.66 | -20.37 | -19.33 | -21.32 | -- | -- | -8,968.40 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 30 Jun 2024 | 11.55m | 8.63% |
Casdin Capital LLCas of 30 Jun 2024 | 8.45m | 6.31% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 8.21m | 6.13% |
Bellevue Asset Management AGas of 30 Jun 2024 | 6.38m | 4.76% |
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 2024 | 4.85m | 3.62% |
SSgA Funds Management, Inc.as of 30 Jun 2024 | 4.25m | 3.17% |
JPMorgan Investment Management, Inc.as of 30 Jun 2024 | 3.41m | 2.55% |
Norges Bank Investment Managementas of 30 Jun 2024 | 3.32m | 2.48% |
Braidwell LPas of 30 Jun 2024 | 3.01m | 2.25% |
Geode Capital Management LLCas of 30 Jun 2024 | 2.36m | 1.77% |